Announcements
- Celyad Oncology announces the termination of its American Depository Receipt program
- Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
- Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
- Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
- Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
More ▼
Key statistics
On Saturday, Celyad Oncology SA (0QFK:LSE) closed at 0.00, -100.00% above its 52-week low of 0.352, set on Dec 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.368 |
Average volume | -- |
---|---|
Shares outstanding | 41.43m |
Free float | 38.27m |
P/E (TTM) | -- |
Market cap | 12.99m EUR |
EPS (TTM) | -0.3287 EUR |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼